Want to see AVBP full AI Analyst Report?
ArriVent BioPharma, Inc. (AVBP) Income Statement
ArriVent BioPharma, Inc. Income Statement
Last quarter (Q2 2026), ArriVent BioPharma, Inc.'s total revenue was $0.00. In Q2, ArriVent BioPharma, Inc.'s net income was $-49.89M. See ArriVent BioPharma, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | |
| $ 177.53M | $ 94.31M | $ 74.59M | $ 36.91M | $ 8.70M | |
| Depreciation and Amortization | $ 0.00 | $ 0.00 | $ 0.00 | $ 36.91M | $ 0.00 |
| $ -166.31M | $ -80.49M | $ -69.33M | $ 0.00 | $ -51.61M | |
| $ -177.53M | $ -94.31M | $ -74.59M | $ -36.91M | $ -8.70M | |
| $ 11.23M | $ 13.82M | $ 5.26M | $ 0.00 | $ -42.91M | |
| $ -166.31M | $ -80.49M | $ -69.33M | $ -36.91M | $ -51.61M | |
| $ -166.31M | $ -80.49M | $ -69.33M | $ -36.91M | $ -51.61M | |
| Per Share Metrics | |||||
| Basic EPS | $ -4.32 | $ -2.56 | $ -2.17 | $ -1.10 | $ -40.44 |
| Diluted EPS | $ -4.32 | $ -2.56 | $ -2.17 | $ -1.10 | $ -40.44 |
| Weighted Average Shares Outstanding | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
| Weighted Average Shares Outstanding (Diluted) | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
Currency in USD
